MedSearchGraphRAG
6 quiz questions available for this topicTake Quiz

Neutropenic sepsis

SNOMED: 4439800041044 words•Updated 03/03/2026
💡

Exam Tips

  • In OSCE/viva, state immediately that neutropenic sepsis is a medical emergency and IV antibiotics must be started within 1 hour.
  • Quote the key threshold: ANC 0.5 x 10^9/L or lower with fever above 38 C and/or sepsis features.
  • Mention that classical inflammatory signs may be muted in neutropenia; normal-looking observations do not exclude early deterioration.
  • Always pair investigations with action: cultures first only if no delay, then broad-spectrum IV antibiotics and senior escalation.
  • Discuss risk stratification (for example MASCC in selected stable adults) but do not delay resuscitation in unstable patients.
  • Include safety points for prescribing: allergy history, renal dose adjustment, and therapeutic drug monitoring for nephrotoxic agents.

Definition

Neutropenic sepsis is sepsis occurring in a person with neutropenia, most commonly after anticancer therapy, and is a time-critical oncological emergency. In UK practice, a pragmatic definition is neutrophils 0.5 x 10^9/L or lower (or expected to fall below this) plus fever above 38.0 C and/or clinical features of sepsis with new infection-related organ dysfunction.

Pathophysiology

Neutrophils are central to early innate immune control of bacterial and fungal invasion; when marrow production is suppressed (classically by cytotoxic chemotherapy), mucosal injury and neutrophil depletion allow rapid microbial translocation and bloodstream infection. The highest risk period is the post-chemotherapy neutrophil nadir (typically about days 5-10 after treatment), especially if neutropenia is profound or prolonged beyond 7 days. A dysregulated host inflammatory response then drives endothelial injury, capillary leak, microvascular thrombosis, tissue hypoperfusion, and organ dysfunction (sepsis/septic shock). Common pathogens include Gram-positive cocci (for example Staphylococcus aureus, streptococci, enterococci) and Gram-negative bacilli (for example Escherichia coli, Klebsiella spp, Pseudomonas aeruginosa), with fungal disease (Candida/Aspergillus) in prolonged severe neutropenia. See Figure: chemotherapy neutrophil nadir curve and sepsis cascade in standard oncology/immunology textbooks.

Risk Factors

  • Profound neutropenia (ANC 0.5 x 10^9/L or lower) or rapidly falling neutrophil count
  • Prolonged neutropenia (>7 days), especially after intensive AML chemotherapy or stem-cell transplantation
  • Recent cytotoxic chemotherapy (mucositis and epithelial barrier injury)
  • Haematological malignancy (higher risk than many solid tumours)
  • Previous episode of febrile neutropenia or neutropenic sepsis
  • Concurrent corticosteroids or other immunosuppressants (for example methotrexate, azathioprine, anti-TNF agents, rituximab)
  • Central venous access device or total parenteral nutrition
  • Comorbidity burden (for example diabetes, renal or liver disease), malnutrition, prolonged admission, recent surgery
  • Age extremes (infants and older adults)

Clinical Features

Symptoms

  • Fever or rigors (but fever may be absent in severe immunosuppression)
  • Malaise, profound fatigue, reduced oral intake
  • Sore throat, mouth pain/ulcers, dysphagia (mucositis-related entry point)
  • Cough, breathlessness, pleuritic chest pain
  • Abdominal pain, diarrhoea, perianal discomfort
  • Dysuria or urinary frequency
  • Confusion, dizziness, reduced urine output as red flags for organ dysfunction

Signs

  • Temperature >38.0 C or hypothermia
  • Tachycardia, tachypnoea, hypotension, prolonged capillary refill
  • Oxygen desaturation or increased work of breathing
  • Altered mental state
  • Potentially minimal localising inflammatory signs because neutrophil response is blunted
  • Evidence of line-site infection, oral candidiasis/mucositis, or focal chest/abdominal findings
  • Features of septic shock (persistent hypotension and raised lactate despite fluid resuscitation)

Investigations

Full blood count with differential:Neutrophils 0.5 x 10^9/L or lower (or expected imminent fall), often with other cytopenias
Blood cultures (peripheral and from each lumen of any central line) before antibiotics if no delay:May identify bacteraemia (Gram-positive or Gram-negative organisms), but can be negative
Serum lactate and venous/arterial blood gas:Lactate elevation suggests tissue hypoperfusion and higher mortality risk
Urea, creatinine, electrolytes and liver profile:Acute kidney injury, electrolyte disturbance, or hepatic dysfunction from sepsis
CRP and/or procalcitonin (where used locally):Inflammatory markers may rise but can be attenuated in profound immunosuppression
Urinalysis and urine culture:Possible urinary focus; pyuria may be limited in neutropenia
Chest X-ray (or CT chest if persistent fever/high suspicion):May show pneumonia; early radiology can be subtle despite significant infection
Targeted cultures/imaging (stool, skin/line swabs, abdominal CT, fungal biomarkers such as galactomannan in selected patients):Helps define occult source, invasive fungal disease, or line-related sepsis

Management

Lifestyle Modifications

  • Give explicit safety-net advice to patients on systemic anticancer therapy: if temperature is 38.0 C or above, rigors, or feeling acutely unwell, seek emergency assessment immediately (do not self-manage at home).
  • Provide neutropenic sepsis alert information/card and reinforce infection-prevention basics (hand hygiene, prompt reporting of symptoms, avoid delays to assessment).

Pharmacological Treatment

Immediate empiric IV broad-spectrum antibiotic therapy (within 1 hour of suspected diagnosis)

  • Piperacillin/tazobactam 4.5 g IV every 6 hours

First-line monotherapy in many UK protocols for high-risk neutropenic sepsis. Take cultures first only if this does not delay treatment. Contraindications/safety: avoid in serious beta-lactam hypersensitivity; adjust dose in renal impairment; monitor for C. difficile diarrhoea, cytopenias, renal/hepatic adverse effects.

Alternative empiric regimen when severe penicillin allergy or local resistance patterns dictate

  • Meropenem 1 g IV every 8 hours
  • Aztreonam 2 g IV every 8 hours (often combined with a Gram-positive agent per local policy)

Choice should follow local microbiology guidance and prior culture history. Meropenem has cross-reactivity risk lower than penicillins but still needs allergy assessment; both require renal dose adjustment.

Add-on agents for specific indications (not routine for all)

  • Vancomycin IV (loading and maintenance by weight/renal function and trough/AUC monitoring)
  • Teicoplanin IV (loading regimen then once daily maintenance)
  • Gentamicin 5-7 mg/kg IV once daily (if septic shock or resistant Gram-negative concern, per local protocol)

Reserve for suspected line/skin infection, MRSA risk, haemodynamic instability, or resistant organisms. Safety: nephrotoxicity/ototoxicity risk with glycopeptides and aminoglycosides; close therapeutic drug monitoring required.

Antifungal therapy for persistent/recurrent fever despite adequate antibacterial therapy in prolonged neutropenia

  • Liposomal amphotericin B 3 mg/kg IV once daily
  • Caspofungin 70 mg IV on day 1, then 50 mg IV once daily

Consider after specialist review, especially in expected prolonged profound neutropenia or clinical/radiological fungal clues. Safety: amphotericin-associated nephrotoxicity and infusion reactions; monitor renal function, potassium, magnesium, and liver tests.

Adjunctive sepsis care

  • IV crystalloids (for example 500 mL boluses of balanced crystalloid, reassessing frequently)
  • Noradrenaline infusion for persistent hypotension after fluids (critical care setting)

Follow sepsis resuscitation principles and early critical care escalation. Avoid fluid overload in cardiac/renal comorbidity; insert urinary catheter when needed for output monitoring.

Surgical / Interventional

  • Urgent source control where indicated (for example drainage/debridement of abscess, management of perforation or necrotic focus).
  • Assess and remove/replace infected central venous catheter when line sepsis is likely and clinically feasible.
  • Early ICU involvement for refractory shock or evolving multi-organ failure.

Complications

  • Septic shock and death
  • Multi-organ dysfunction (AKI, respiratory failure/ARDS, encephalopathy, cardiac dysfunction)
  • Disseminated intravascular coagulation and thromboembolic events
  • Invasive fungal or atypical opportunistic infections
  • Hospital-acquired infection and antimicrobial resistance
  • Post-sepsis syndrome (physical, cognitive, and psychological morbidity)
  • Cancer treatment interruption or dose reduction, potentially affecting oncological outcomes

Prognosis

Outcome depends on speed of recognition, timeliness of first-dose antibiotics, depth/duration of neutropenia, organism virulence, and organ dysfunction at presentation. Neutropenic sepsis carries substantially higher mortality than uncomplicated febrile neutropenia, with reported adult mortality reaching around 10-20% or higher in complicated cases; prognosis worsens with septic shock, persistent lactataemia, and delayed treatment.

Sources & References

✅NICE Guidelines(1)

📖Textbook References(20)

  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1317)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1423)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1423)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1422, 1423)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1424)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1316, 1317)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1474, 1475)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 401)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 874)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 561, 562)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 401)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 553)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 1, 2, 3)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 562)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 400, 401)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 873, 874)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 400, 401)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 3)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 156, 157)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 157)[context]

Sources

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz